Subcutaneous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy – Neurologist, Nursing and Patient Perspectives

<p />

[1]  D. Vinh,et al.  Prefilled syringes for immunoglobulin G (IgG) replacement therapy: clinical experience from other disease settings , 2018, Expert opinion on drug delivery.

[2]  D. Cornblath,et al.  IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. , 2018, Immunotherapy.

[3]  G. Tedeschi,et al.  Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin , 2018, Clinical Neurophysiology.

[4]  G. L. Masson,et al.  Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial , 2018, The Lancet Neurology.

[5]  T. Harbo,et al.  Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs , 2017, Journal of the Neurological Sciences.

[6]  L. Sposato,et al.  Subcutaneous versus intravenous immunoglobulin for chronic autoimmune neuropathies: A meta‐analysis , 2017, Muscle & nerve.

[7]  L. Lopiano,et al.  Subcutaneous vs. intravenous immunoglobulin in CIDP: pharmacokinetic and clinical response , 2016, Journal of the peripheral nervous system : JPNS.

[8]  J. Lawo,et al.  Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency , 2016, Journal of Clinical Immunology.

[9]  J. Jakobsen,et al.  Headache and Nausea after Treatment with High‐Dose Subcutaneous versus Intravenous Immunoglobulin , 2015, Basic & Clinical Pharmacology & Toxicology.

[10]  R. Hughes,et al.  Chronic in fl ammatory demyelinating polyradiculoneuropathy: from pathology to phenotype , 2022 .

[11]  A N N Gardulf,et al.  Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease , 2015, Clinical and experimental immunology.

[12]  R. Hadden,et al.  Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction , 2015, Therapeutic advances in neurological disorders.

[13]  J. Jakobsen,et al.  Subcutaneous immunoglobulin preserves muscle strength in chronic inflammatory demyelinating polyneuropathy , 2014, European journal of neurology.

[14]  W. Robberecht,et al.  Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study) , 2013, Journal of the peripheral nervous system : JPNS.

[15]  H. Hartung,et al.  Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG – the ICE study , 2013, European journal of neurology.

[16]  L. Lopiano,et al.  Economic and quality of life evaluation of different modalities of immunoglobulin therapy in chronic dysimmune neuropathies , 2012, Journal of the peripheral nervous system : JPNS.

[17]  R. Nelson,et al.  Pharmacokinetics of Subcutaneous IgPro20 in Patients with Primary Immunodeficiency , 2011, Clinical pharmacokinetics.

[18]  J. Pollard,et al.  CIDP – the relevance of recent advances in Schwann cell/axonal neurobiology , 2011, Journal of the peripheral nervous system : JPNS.

[19]  M. Bakkers,et al.  Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies , 2011, Neurology.

[20]  S. Spector,et al.  Efficacy and Safety of a New 20% Immunoglobulin Preparation for Subcutaneous Administration, IgPro20, in Patients With Primary Immunodeficiency , 2010, Journal of Clinical Immunology.

[21]  J. Pollard,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision , 2010, European journal of neurology.

[22]  R. Hughes,et al.  Clinical applications of intravenous immunoglobulins in neurology , 2009, Clinical and experimental immunology.

[23]  R. Hughes.  Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial , 2009, Expert review of neurotherapeutics.

[24]  F. Bonilla.  Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. , 2008, Immunology and allergy clinics of North America.

[25]  M. Berger.  Subcutaneous administration of IgG. , 2008, Immunology and allergy clinics of North America.

[26]  F. Käsermann,et al.  Investigations of prion and virus safety of a new liquid IVIG product. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[27]  H. Hartung,et al.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial , 2008, The Lancet Neurology.

[28]  M. Berger.  Subcutaneous immunoglobulin replacement in primary immunodeficiencies. , 2004, Clinical immunology.

[29]  G. Comi,et al.  Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy , 2001, Annals of neurology.